INVEST IN IMETABOLIC BIOPHARMA TODAY!
Our technology-powered iPlatform™ pipeline removes the roadblocks that typically make drug development slow, expensive, and inefficient, with the aim to put lifesaving treatments in the hands of communities everywhere.
Our revolutionary approach to drug development has already landed us three strategic technology and pharma industry partnership deals, five disease therapeutic asset programs already in motion, and four additional programs prepared to go online.
We are led by a passionate and highly talented team who understands the human nature of the work we do. We are determined to apply our collective knowledge and experience to bring hope, empowerment, and opportunity to our investors and their communities.
At iMBP, we are the next stage of biotech evolution. We are combining innovative technology with biotechnology as part of our proprietary, cutting-edge “TechBio” approach to biopharma. We give communities the opportunity to invest in their own health as we improve the way drugs are discovered to make them more effective and affordable. We have strategic partnerships in place and drug candidates in development in our key markets of metabolic, cardiovascular, and neurodegenerative diseases. The company is pre-revenue and in the prototype phase.
iMBP is developing a revolutionary approach to drug discovery to help people live longer, healthier, and happier lives with their loved ones. Our founder, Chairman, and CEO Dr. Urban A. Kiernan, Ph.D. is a seasoned BioTech leader with decades of industry business and scientific research experience. However, his passion is what drives him beyond what any academic or work experience could ever afford him.
"The feeling of helplessness I experienced when my first wife died from cancer was devastating. Then, a single Dad with two little girls, the world turned upside-down. From this pain, I recognized the utopic potential the biopharma industry has to offer... and that is the power to keep families together... for just one more... one more memory to hold onto. You cannot put a price tag on that. This is my passion and this is why I created iMBP."
– Dr. Urban A. Kiernan –
Husband, Father, Founder & CEO of iMBP
The Problem & Our solution
Today’s developmental process for new, lifesaving drugs is complex, expensive, and time-consuming. The current industry solution is to simply spend more money, resulting in over-expensive therapeutics with marginal benefits. Ultimately, the deficiencies of this system places the cost burden on the people who need these therapeutic solutions most.
Our Solution was the development of iPlatform™, our proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably. This is the value that TechBio offers to you and your loved ones. Enabled through our partner Amazon Web Services (AWS), iPlatform™ is rapidly evolving and already producing drug asset leads for the expansion of the iMBP drug pipeline.
the market & Our Traction
Our drug asset efforts are currently focused in three primary areas: metabolic disease, cardiovascular disease, and neurodegenerative disease (Alzheimer’s Disease).
Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life, including:
"Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance."
– John Higgins –
CEO at Ligand Pharmaceuticals
Through this raise, we offer communities the opportunity to directly invest in solutions for their own health.
BioTech investment opportunities are typically reserved for an elite circle of the same investors, and we are eager to break this cycle by sharing with you our unique equity crowdfunding campaign.
With major partnerships in place and multiple drug candidates already in development, we are ready to change the way we care for our communities and hope to give loved ones and families as much time together as possible. Invest in iMBP today and become a part of this unique opportunity with us.
iMetabolic Biopharma Corporation (iMBP) is an early-stage drug discovery company innovating at the intersection of technology and biotechnology to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones. Currently, we are pre-market, advancing five different disease asset programs, and in the process of developing a proprietary technological platform for the discovery of more effective and less expensive drugs. This will allow us to continuously expand our drug pipeline while increasing company value.
Stephen Adam Munk
Interim - COO and Board Director
David F Hendren
Chief Business Officer
Secretary and General Counsel
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
What is a Convertible Note?
A convertible note offers you the right to receive Preferred Stock in iMetabolic BioPharma. The amount of Preferred Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $5,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 10.00% discount on the price the new investors are paying. You also receive 3.50% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Preferred Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).
*Annual Interest Rate subject to adjustment based on bonuses below.
Loyalty Bonus | 5% Bonus
As you have previously invested in iMetabolic BioPharma, you are eligible for additional bonus interest.
Invest within the first 72 hours and receive 15% bonus interest.
Invest within the first week and receive 10% bonus interest.
Invest within the first two weeks and receive 5% bonus interest.
$500+ | Knight
Invest $500+ and receive + 5% bonus interest.
$1,000+ | Baron
Invest $1,000+ and receive + 7% bonus interest.
$5,000+ | Duke
Invest $5,000+ and receive + 10% bonus interest + a Membership to the Exclusive iMBP VIP Forum.
$10,000+ | Prince
Invest $10,000+ and receive + 15% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
$20,000+ | Emperor
Invest $20,000+ and receive + 20% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonuses from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
iMetabolic BioPharma will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 3.85% instead of 3.5%.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Loyalty Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.
You may have heard about orphan drug designation but what does it mean?
Orphan drug designation allows for streamlined regulatory pathways that will cut years and save millions of dollars in developmental costs. Why is this important?
Using orphan drug status helps get a drug through clinical trials faster and iMBP has a program in the works. This saves both time and millions of dollars in R&D costs.
Success with the FDA is a major value generating hurdle and would lead to revenue generation sooner. And that means boost ROI for investors like you.
As orphan diseases have patients with high unmet medical need. It is a of way helping people who have no real solutions yet, and that’s our mission at iMBP.
Become an early investor.
Dr. Kiernan explains the different lipoprotein particle types that make up "Bad" cholesterol and how Apolipoprotein B is a unifying hallmark of them all.
Join Dr. Urban A. Kiernan and iMBP on their mission to create better cardiovascular drugs while improving how they are made to make them more effective and affordable.
Our revolutionary technology has landed us key strategic partnership with Amazon Web Services. This is such an honor and great opportunity to work with this industry giant, and shows the dedication and trust they have in us and our mission to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones.
Join us today and make a positive impact in the biopharma industry!
Why did David Hendren get involved in iMBP? He’s excited for a number of reasons!
Your investment is already being deployed to create value in the company.
Our efforts are largely focused on the development of iMBP science. This includes both our technology and our therapeutic molecules.
A small portion of your money is being spent to expand the out reach of our campaign and continue to build our community. We have hundreds of non-investor followers and we are looking to gain their support and join in our cause.
Thank you again so much for joining us!
-Dr. Urban A. Kiernan
iMBP Founder and CEO
Previously, only the elite or venture capitalists were able to invest in startups. Until 2016, it was illegal for everyday investors to invest in startups. But not anymore.
Since 2016, retail investors have invested $2.3 billion in US startups. And the gains can be astronomical, with some industries seeing a return of 10,000% - 60,000%.
But don’t just in invest in any startup. Invest in one that could revolutionize the way drugs are discovered!
At iMBP, our mission is to change the way drugs are discovered to bring more effective therapeutics in a more effective and efficient manner.
iMBP is honored to work with top experts and industry leaders helping advance our mission to revolutionize the biopharma industry. And we want you to get to know them to feel confident in your investment!
Spotlight: David Hendren, Chief Business Officer at iMBP
David has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, biomedical technology, life science, digital health, and related technology and service areas.
He brings a deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel.
Join David and the rest of our expert team by becoming an early owner of iMBP. Let’s make an impact!
Approximately 6 million Americans currently live with Alzheimer’s disease, a progressive neurodegenerative disease that so far has no cure and cannot be reversed.
Newly approved treatments do show some effectiveness in either slowing the progression of the disease or improving symptoms, but they come with significant side effects that may be potentially life threatening. iMBP wants to change this!
Our novel therapeutic program is still in the discovery phase, but its innovation makes it a stand-alone approach in the Alzheimer’s disease drug space.
But we can’t do it without help and support from you. Become an early owner or share this opportunity with your friends so we can provide hope in the fight against Alzheimer’s disease?
Invest Today and Become a Part of the Innovation!
“How will your investors be able to track your success and company value/investment value after your StartEngine funding window is closed?”
After the campaign closes, your iMetabolic Biopharma investment will be managed through a transfer agent, but we plan to do quarterly announcements that will be sent to the email that was provided to StartEngine. You can also register and scribe to iMBP on its web page and we also urge you to follow us on Facebook, Instagram, LinkedIn and Twitter for the latest news and updates.
If you have questions, don't be shy. Shoot us a message on the campaign's discussion board or reach out on Social Medial. If you do reach out on social, please know that the answer will be posted as an Update while this campaign remains open. We need to ensure that all community members and future members have access to the same information.
We are looking forward to hearing from you!
According to one industry news article*, big drugmakers have started 2023 with their checkbooks out, signing several multibillion-dollar takeovers in what some industry insiders see as the start of an M&A surge focused on snagging blockbuster drugs.
“Every single major pharma company is in shopping mode, right,” said John Maraganore, the former CEO of Alnylam Pharmaceuticals who now advises a range of startups and investment groups, in an interview with Endpoints News. I am generally optimistic that the surge of M&A, which typically catalyzes a lot of bullishness in the biotech market, will ultimately fuel a better second half of the year as inflation comes under better control.”
Now is the time to invest in iMBP, become an early owner!
Members get an extra 10% shares in addition to rewards below!
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
Invest $500+ and receive + 5% Bonus.
Invest $1,000+ and receive + 7% Bonus.
Invest $5,000+ and receive + 10% Bonus + a Membership to the Exclusive iMBP VIP Forum.
Invest $10,000+ and receive + 15% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
Invest $20,000+ and receive + 20% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
4 months ago
4 months ago
4 months ago
4 months ago
4 months ago
4 months ago
4 months ago
5 months ago
5 months ago
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
3 months ago